What You Cared About in 2014
As the year closes, one can’t help but reflect. So, we take a look back at our most popular blog posts from 2014. During the last 12 months, Chempetitive Group’s blog published
The J.P. Morgan Healthcare Conference: Worth the Fuss?
Attendance is by invitation only. There’s no trade show floor. And, good luck tracking down information on speakers and schedules if you’re not invited — a public website for
2014 Snapshot: How the Golden State Fared in Biotech
California is known as an innovator in the national and global life sciences community, garnering more federal biomedical research dollars than any other state in the country. As a
How to Make Twitter Not Fun
Make no mistake. Twitter can be a fun and effective vehicle for engaging with the people who influence your company’s success. But for those in highly regulated industries such a
5 Best Tactics for Writing Lists Readers Can’t Refuse
The online publishing world seems to be going bananas (b-a-n-a-n-a-s) for list-based articles and blog posts. Why? It’s all about the clicks. Whether “Top 10”-type lists deli
Usability: Making Better Websites with Dead Simple User Experience
Let’s get something straight: We’re all marketing to humans. Yes, customers’ perspectives, experiences and industries may differ — even within the life sciences industry. B
Replacing Adderall: Medicines to Change the World (Part I)
It’s a sad beginning to my series on medications set to change society and the way we live our lives. Shares in the promising biotech Alcobra Pharma plummeted 50 percent this wee
When Over-sharing Is a Good Thing: Health Goes Social
Facebook newsfeeds have become a standard outlet for sharing and reading health updates. From migraines to broken bones, people have become quite comfortable telling (and showing)
Life-science-finance-a-palooza
One could make an easy argument that the action in San Francisco this week is as good a prognosticator as there is for the financial health of our industry and it will set the tone
What Can the Shirley Sherrod Story Tell Us All About Judging the FDA
In June, the FDA sent letters to consumer genotyping companies—the companies that analyze your spit and tell you what diseases you’re most at risk of contracting—telling them